Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI

Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI - Effectiveness of intracoronary bolus abciximab application for No-Reflow or Slow flow phenomenon during PCI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006002

Enrollment

Registered

2011-07-19

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients suffer from No-Reflow or Slow flow phenomenon during PCI

Interventions

Abciximab (+) Abciximab (-)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with coronary artery disease 2. Patients who take aspirin and thienopyridine 3. Informed consent was obtained from patients

Exclusion criteria

Exclusion criteria: 1.with hemorrhagic diathesis and/or hypercoagulability 2.under emergent PCI 3.received thrombolytic therapy before PCI 4.more than twice the value of standard CPK and CPK-MB 5.be pregnant or nursing 6.with unprotected LMT disease

Design outcomes

Primary

Measure	Time frame
Rate of attrition of ST elevation ratio :Comparison between at 30 minutes after PCI and at the time of maximum ST elevation	—

Secondary

Measure	Time frame
1. Rate of ST re-elevation after intracoronary bolus application of drug(s) 2. TIMI flow after PCI 3. Myocardial blush grade after PCI 4. Maximum value of CPK/CPK-MB after PCI 5. MACCE at 30 days / 1 year after PCI 6. Existence or nonexistence of serious hemorrhagic complication 7. Angiographical phenomenon at follow-up CAG	—

Countries

Japan

Contacts

Public ContactDaiji Hasegawa

Kurashiki Central Hospital Department of Cardiology

dh10969@kchnet.or.jp086-422-0210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026